Loading
institutionsInstitution
Montefiore Einstein Comprehensive Cancer Center
The Bronx's NCI comprehensive cancer centre, where Joseph Sparano ran TAILORx, the trial that let most women with early HR-positive breast cancer skip chemotherapy.
Also called: Albert Einstein Cancer Center
Overview
The Albert Einstein Cancer Center has been NCI-designated since 1972 and, as Montefiore Einstein Comprehensive Cancer Center, now holds comprehensive status while serving one of the poorest urban counties in the United States. Joseph Sparano chaired TAILORx from here for ECOG-ACRIN, showing that a mid-range Oncotype DX recurrence score identifies women who do not need adjuvant chemotherapy. John Condeelis's intravital imaging revealed the TMEM 'doorways' through which breast cancer cells enter the bloodstream; Ulrich Steidl and Amit Verma lead work on MDS and leukaemia stem cells. Director Edward Chu is a GI oncologist and cancer pharmacologist.
Location
Bronx, NY, US
Type
cancer center · Albert Einstein College of Medicine
Newsweek 2026 oncology rank
Not in top 300 listing used
NCI designation
comprehensive
OnCo score
#99 · 39 points (0 Newsweek + 15 NCI + 24 from 12 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-16.
Matched to Montefiore Einstein Comprehensive Cancer Center, including child institutions. 49 works · 182 citations · 55% open access · 14% clinical trials · 4% reviews.
Oncology works per year
02022
42023
232024
132025
92026
Most works
- Chaoyuan Kuang9 works
- Balázs Halmos9 works
- Jee‐Young Moon7 works
- Yvonne M. Saenger5 works
- Chenxin Zhang5 works
- Haiying Cheng4 works
- Fernand Bteich4 works
- Shalom Kalnicki3 works
- Ioannis Mantzaris3 works
- Ari M. Vanderwalde3 works
Most cited
- Breast cancer (TAILORx)
- Metastasis imaging
- MDS and leukaemia stem cells
- Bronx community oncology
Similar pages
- PersonJoseph A. Sparano
Shares TAILORx, Oncotype DX, HR-positive / HER2-negative breast cancer.
- PersonKathy S. Albain
Shares TAILORx, Oncotype DX, HR-positive / HER2-negative breast cancer.
- PairingGene-expression assay → chemotherapy omission
Shares TAILORx, Oncotype DX, HR-positive / HER2-negative breast cancer.
- InstitutionVCU Massey Comprehensive Cancer Center
Shares NCI-Designated Cancer Centers, Trials do not represent the people who get cancer, National Cancer Institute (NIH), Acute myeloid leukaemia.
- InstitutionBarbara Ann Karmanos Cancer Institute
Shares NCI-Designated Cancer Centers, Trials do not represent the people who get cancer, National Cancer Institute (NIH), HR-positive / HER2-negative breast cancer.
- InstitutionCancer Center at Illinois
Shares Optical & fluorescence imaging, NCI-Designated Cancer Centers, National Cancer Institute (NIH).
- InstitutionUniversity of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Shares NCI-Designated Cancer Centers, Trials do not represent the people who get cancer, National Cancer Institute (NIH), HR-positive / HER2-negative breast cancer.
- InstitutionSylvester Comprehensive Cancer Center, University of Miami
Shares Trials do not represent the people who get cancer, Myelodysplastic syndromes / neoplasms (MDS), National Cancer Institute (NIH), Acute myeloid leukaemia.
cancers
technologies
drugs
EstablishedGene-expression prognostic/predictive assay